NovoCure Ltd — Director's Dealing 2020

Mar 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2020-03-04

Reporting Person: GROENHUYSEN WILHELMUS CM (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-04	Options to Buy Ordinary Shares	$21.15	G	84483	Disposed	2028-02-26	Ordinary Shares (84483.0)	Direct
2020-03-04	Options to Buy Ordinary Shares	$21.15	G	84483	Acquired	2028-02-26	Ordinary Shares (84483.0)	Indirect
2020-03-04	Options to Buy Ordinary Shares	$7.15	G	219373	Disposed	2027-02-21	Ordinary Shares (219373.0)	Direct
2020-03-04	Options to Buy Ordinary Shares	$7.15	G	219373	Acquired	2027-02-21	Ordinary Shares (219373.0)	Indirect
2020-03-04	Options to Buy Ordinary Shares	$21.9	G	300030	Disposed	2026-01-12	Ordinary Shares (300030.0)	Direct
2020-03-04	Options to Buy Ordinary Shares	$21.9	G	298386	Acquired	2026-01-12	Ordinary Shares (298386.0)	Indirect
2020-03-04	Options to Buy Ordinary Shares	$21.9	G	1644	Acquired	2026-01-12	Ordinary Shares (1644.0)	Indirect

Footnotes

F1: Currently exercisable.

F2: By The 2020 Groenhuysen Family Trust. Mr. Groenhuysen does not disclaim beneficial ownership.

F3: By The 2020 Groenhuysen Annuity Trust. Mr. Groenhuysen does not disclaim beneficial ownership.